All In Biotech

Drug Trial Radar · NCT03126019

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

126

Actual

Start

Mar 14, 2018

Primary completion

Feb 26, 2021

Study completion Jun 7, 2024

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Apr 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma.

Conditions

  • Lymphoma

Interventions

  • ParsaclisibDrug

    Parsaclisib tablets administered orally with water and without regard to food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate With Parsaclisib Based on Lugano Classification Response CriteriaTime frame: Up to approximately 148 weeks

Locations

83 sites in 13 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates - Biltmore Cancer Center

    Phoenix, Arizona

  • Beverly Hills Cancer Center

    Beverly Hills, California

  • Synergy Hematology and Oncology Medical Associates

    Los Angeles, California

  • St. Joseph Heritage Healthcare

    Santa Rosa, California

  • American Institute of Research Corporate Office

    Whittier, California

  • Cancer Center of Central Connecticut

    Southington, Connecticut

  • Florida Cancer Specialists & Research Institute

    Fort Myers, Florida

  • Asclepes Research Centers

    Spring Hill, Florida

  • Clinical Trials of Swla Llc

    Lake Charles, Louisiana

  • Saint Agnes Hospital

    Baltimore, Maryland

  • Barbara Ann Karmanos Cancer Hospital

    Detroit, Michigan

  • Hattiesburg Clinic Hematology

    Hattiesburg, Mississippi

  • Saint Luke'S Hospital

    Kansas City, Missouri

  • Sarah Cannon Research Institute

    Kansas City, Missouri

  • Clinical Research Alliance, Inc.

    New Hyde Park, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Gabrail Cancer Center

    Canton, Ohio

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania

  • Charleston Hematology Oncology Associates Pa

    Charleston, South Carolina

  • Tennessee Oncology

    Nashville, Tennessee

  • Renovatio Clinical Consultants Llc

    Spring, Texas

  • University of Washington

    Seattle, Washington

  • St Vincent'S Hospital Sydney

    Darlinghurst, Australia

  • Western Health

    St Albans, Victoria, Australia

  • Border Medical Oncology

    Wodonga, Victoria, Australia

  • Saint John Regional Hospital

    Saint John, New Brunswick, Canada

  • Sunnybrook Health Science Centre

    Toronto, Ontario, Canada

  • Santa Cabrini Hospital

    Montreal, Quebec, Canada

  • University Hospital Hradec Kralove

    Hradec Králové, Czechia

  • Fakultni Nemocnice Ostrava

    Ostrava, Czechia

  • University Hospital Kralovkse Vinohrady

    Prague, Czechia

  • Univerzita Karlova V Praze 1. Lekarska Fakulta

    Prague, Czechia

  • Fakultni Nemocnice V Motole

    Prague, Czechia

  • Aalborg University Hospital

    Aalborg, Denmark

  • Odense Universitetshospital (Ouh) (Odense University Hospital)

    Odense C, Denmark

  • Bag Arnoldstr. Dresden

    Dresden, Germany

  • University Medical Center Freiburg

    Freiburg im Breisgau, Germany

  • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

    Mainz, Germany

  • University Hospital Mannheim

    Mannheim, Germany

  • Semmelweis Egyetem

    Budapest, Hungary

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.